Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
A Trial of ZL-1201 in Subjects With Advanced Cancer

First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer

  • 0 views
  • 19 Feb, 2024
Impact of a Resource-based Life Review Intervention on Advanced Cancer Patients

The main objective of the present study is to evaluate the effects of the Revie intervention on the self-esteem of patients diagnosed with an advanced cancer. A pragmatic, two-arm parallel-group, waitlist randomized controlled trial is conducted. The study takes place in the oncology department of the University Hospitals of Geneva …

cancer
advanced cancer
  • 0 views
  • 19 Feb, 2024
Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer

This study will compare the effectiveness of the Masterful supportive care intervention with that of the non-faith-based active control supportive care intervention, which uses the American Cancer Society's patient education materials, for Muslim patients who have advanced cancers.

cancer
advanced cancer
  • 0 views
  • 19 Feb, 2024
Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer

Assessment of efficacy of primary cyto-reductive surgery in patients with advanced primary epithelial ovarian cancer in Comparison to patients receiving neo-adjuvant chemotherapy (NAC) followed by surgery in complete excision of the tumor reaching R0 without significant morbidity.

epithelial ovarian cancer
adjuvant
cancer
ovarian cancer
  • 0 views
  • 19 Feb, 2024
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab. The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the …

liver metastasis
blood transfusion
endocrine disorder
tilsotolimod
colorectal cancer
  • 0 views
  • 19 Feb, 2024
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

cancer treatment
HER2
pancreatic cancer
solid neoplasm
solid tumor
  • 0 views
  • 19 Feb, 2024
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Eligibility People age 18 and older who have a rare, advanced cancer that has progressed after receiving standard treatment, or for which no effective therapy exists. Design Participants will be screened with medical history and physical exam.

thymic carcinoma
lymphoma
biopsy tissue
serous cystadenocarcinoma
carcinoma lung
  • 0 views
  • 19 Feb, 2024
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …

metastasis
solid tumour
cancer
measurable disease
hla-g
  • 0 views
  • 19 Feb, 2024
Microbiome and Rectal Cancer

The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.

adenocarcinoma
rectal carcinoma
adenocarcinoma of rectum
rectal cancer
cancer
  • 0 views
  • 19 Feb, 2024
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

advanced malignant solid tumor
anthracyclines
systemic therapy
carcinoma
cancer
  • 0 views
  • 19 Feb, 2024